25 | EARLY AND MAINTAINED TREAT-TO-TARGET RESPONSE WITH IXEKIZUMAB UP TO 5 YEARS IN MODERATE-TO-SEVERE PSORIASIS: A POST-HOC ANALYSIS OF UNCOVER-3
TL;DR
This post-hoc analysis examined T2T outcomes in patients from UNCOVER-3 receiving the label dose of ixekizumab receiving the label dose of ixekizumab, finding early and maintained response was defined as achievement of T2T goals at Week12 maintained at 5 years (Week264).
Abstract
Background. The National Psoriasis Foundation recommends evaluating treatment response at Week12, with a target body surface area (BSA) ≤1% affected and an acceptable response of BSA≤3%1. European consensuses emphasize a shift from relative outcomes such as Psoriasis Area and Severity Index (PASI) scores of 90/100 towards absolute endpoints including PASI≤22. Early achievement and long-term maintenance of these treat-to-target (T2T) outcomes are important, providing patients with more days of minimal disease burden.Methods. UNCOVER-3 (NCT01646177) was a multicenter, randomized, double-blind, placebo-controlled study of ixekizumab in patients with moderate-to-severe psoriasis3. This post-hoc analysis examined T2T outcomes in patients from UNCOVER-3 receiving the label dose of ixekizumab (N=385). Baseline demographics and patient characteristics were similar to those previously presented4. Early and maintained response was defined as achievement of T2T goals at Week12 maintained at 5 years (Week264). Assessments included absolute PASI≤2, absolute PASI≤1, BSA≤3%, and BSA≤1%, reported as observed. No statistical testing for significance was conducted.Results. At Week12, absolute PASI